PEG-PLGA Block Copolymers
Amphiphilic Diblock & Triblock Copolymers for Advanced Drug Delivery
The Best of Both Worlds
PEG-PLGA block copolymers combine hydrophilic polyethylene glycol (PEG) with biodegradable PLGA, creating amphiphilic systems ideal for micellar drug delivery.
Our portfolio features FDA-relevant materials designed for spontaneous self-assembly into nanoparticles, micelles, and thermosensitive hydrogels. These polymers offer precisely tunable degradation and stealth properties for systemic and localized delivery.
Key Capabilities
- Spontaneous micelle formation (10-100 nm)
- Solubilization of hydrophobic drugs (e.g., Paclitaxel)
- Thermosensitive sol-gel transition at body temperature
- Extended circulation via PEG "stealth" corona
Available Architectures
Explore our range of diblock and triblock systems for specific delivery needs.
| Architecture | Structure | Key Features | Applications |
|---|---|---|---|
| PEG-PLGA | Diblock (A-B) | Spherical micelles, CMC control, simple synthesis | Nanoparticles, micellar delivery, coatings |
| PLGA-PEG | Diblock (B-A) | Reverse orientation, different self-assembly | Surface modification, PEGylation |
| PLGA-PEG-PLGA | Triblock (A-B-A) | Thermosensitive gelation, bridging micelles | Injectable hydrogels, in situ gels, 3D printing |
| PEG-PLGA-PEG | Triblock (B-A-B) | Enhanced hydrophilicity, unique gelation | Tissue engineering, cell encapsulation |
PLGA Block Options
The LA:GA ratio of the PLGA block dictates the release and degradation profile.
Fastest Release
Degradation: 1-2 months. Most hydrophilic PLGA block.
Balanced Performance
Degradation: 4-5 months. Most versatile for systemic delivery.
Extended release
Degradation: 5-6 months. Slower degradation for long-term depots.
Molecular Weight Configurations
| Architecture | PEG MW (Da) | PLGA MW (Da) | Total MW Range (Da) | Properties |
|---|---|---|---|---|
| PEG-PLGA Diblock | 2,000 - 10,000 | 5,000 - 50,000 | 7,000 - 60,000 | Lower CMC, stable micelles |
| PLGA-PEG Diblock | 2,000 - 10,000 | 5,000 - 50,000 | 7,000 - 60,000 | Surface-active, stealth coating |
| PLGA-PEG-PLGA Triblock | 1,000 - 6,000 | 1,000 - 10,000 (each) | 3,000 - 26,000 | Sol-gel transition 20-40°C |
| PEG-PLGA-PEG Triblock | 1,000 - 5,000 (each) | 2,000 - 15,000 | 4,000 - 25,000 | Enhanced hydrogel stability |
Custom ratios available: Contact us for specific PEG:PLGA ratios and LA:GA combinations.
Key Advantages
Stealth Properties
PEG corona reduces protein adsorption, prolongs circulation time.
Enhanced Solubility
Micelles solubilize hydrophobic drugs up to 100-fold.
Self-Assembly
Spontaneous formation in water, 10-100 nm diameter.
Injectable Systems
Triblocks form thermosensitive gels at body temperature.
Diblock vs Triblock Comparison
| Property | Diblock | Triblock |
|---|---|---|
| Self-Assembly | Micelles | Micelles + Gels |
| CMC | Lower | Higher |
| Thermosensitivity | Limited | Strong |
| Best For | IV injection | Local Depots |
Applications by Drug Delivery Need
Micellar Delivery
For hydrophobic anticancer agents like Paclitaxel.
Targeted Nanoparticles
Functionalized PEG for active targeting of tumors.
Injectable Depots
In situ gelation for localized drug release.
Tissue Engineering
Cell encapsulation and biodegradable scaffolds.
Formulation Examples
| Formulation Type | Polymer System | Drug Example | Release Duration |
|---|---|---|---|
| Polymeric Micelles | PEG5k-PLGA20k (75:25) | Paclitaxel, Doxorubicin | Hours to days (IV) |
| Nanoparticles | PEG2k-PLGA15k (50:50) | siRNA, Proteins | 1-2 weeks |
| Injectable Hydrogel | PLGA1.5k-PEG1.5k-PLGA1.5k (75:25) | Insulin, Growth factors | 2-4 weeks |
| Depot Injection | PLGA3k-PEG1k-PLGA3k (85:15) | Peptides, Biologics | 1-3 months |
Technical Specifications Summary
| Parameter | Specification |
|---|---|
| Synthesis Method | Ring-opening polymerization (Sn-catalyzed) |
| Polydispersity (Đ) | < 1.5 (narrow distribution) |
| PEG Functionality | mPEG, OH-PEG, NH₂-PEG, COOH-PEG |
| CMC Range | 1-100 μg/mL (MW dependent) |
| Micelle Size | 10-200 nm (DLS, TEM verified) |
| Storage | -20°C, desiccated, protect from moisture |
| Purity | > 98% (residual monomer < 0.5%) |
| Characterization | ¹H NMR, GPC, DSC, FTIR, CMC determination |
Why Choose Our PEG-PLGA Portfolio?
Optimizing bioavailability via advanced copolymer engineering.
Enhanced Bioavailability
PEG stealth layer extends circulation time and tumor accumulation via EPR effect.
Versatile Architectures
Diblock for micelles, triblocks for injectable gels and scaffolds.
FDA-Relevant Materials
Both PEG and PLGA are FDA-approved with extensive safety history.
Ready to Innovate?
Contact our technical team for custom block ratios, functionalization, and application support.